Description of Medical Areas
About the FDA Approved Listings
|
 |
Approved Drugs for Neurology
Drugs Approved in 2008
Durezol (difluprednate); For the treatment of inflammation and pain associated with ocular surgery; Sirion Therapeutics; Approved June 2008
Stavzor (valproic acid delayed release); For the treatment of bipolar manic disorder, seizures and migraine headaches; Banner Pharmacaps; Approved July 2008
Stavzor (valproic acid delayed release); For the treatment of bipolar manic disorder, seizures and migraine headaches; Banner Pharmacaps; Approved July 2008
Vimpat (lacosamide); For the treatment of partial-onset seizures in adults with epilepsy; Schwarz Pharma; Approved October 2008
Xenazine (tetrabenazine); For the treatment of chorea due to Huntington's disease; Prestwick Pharma; Approved August 2008
Xenazine (tetrabenazine); For the treatment of chorea due to Huntington's disease; Prestwick Pharma; Approved August 2008
Drugs Approved in 2007
Exelon (rivastigmine tartrate); For the treatment of Alzheimer's and Parkinson's disease-related dementia; Novartis Pharms; Approved July 2007
Neupro (rotigotine); For the treatment of Parkinson's disease; Schwarz; Approved May 2007
Nuvigil (armodafinil); For the treatment of excessive sleepiness; Cephalon; Approved June 2007
Drugs Approved in 2006
Drugs Approved in 2005
Drugs Approved in 2004
Apokyn (apomorphine hydrochloride); For the treatment of acute, intermittent hypomobility episodes associated with advanced Parkinson’s disease; Mylan Bertek Pharmaceuticals; Approved April, 2004
Lunesta (eszopiclone); For the treatment of insomnia and sleep maintenance; Sepracor; Approved December 2004
Lyrica (pregabalin); For the treatment of pain associated with diabetic peripheral neuropathy and postherpetic neuralgia; Pfizer; Approved December 2004
TYSABRI (natalizumab); For the treatment of relapsing forms of multiple sclerosis; Elan Pharmaceuticals / Biogen Idec; Approved November 2004 -- Updated: Suspended February 2005--Updated: sBLA
Drugs Approved in 2003
Cialis (tadalafil); Oral agent for the treatment for erectile dysfunction; Eli Lilly; Approved December 2003
Levitra (vardenafil); For the treatment of erectile dysfunction related to sexual activity in men; Bayer, GlaxoSmithKline; Approved September 2003
Namenda (memantine HCl); For the treatment of moderate to severe dementia of the Alzheimer’s type.; Forest Laboratories; Approved October 2003
Drugs Approved in 2002
Avinza (morphine sulfate); Extended release capsule for the relief of pain requiring continuous, around-the-clock therapy; Elan; Approved March 2002
Neurontin (gabapentin); Oral treatment for the management of post-herpetic neuralgia (PHN); Pfizer; Approved May 2002
Rebif (interferon beta-1a); Subcutaneous injection for the treatment of relapsing forms of multiple sclerosis; Serono Laboratories; Approved March 2002
Relpax (eletriptan hydrobromide); For the acute treatment of migraine headaches; Pfizer; Approved December 2002
Strattera (atomoxetine HCl); For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults.; Eli Lilly; December 2002
Xyrem (sodium oxybate); For the treatment of cataplexy, a sudden loss of muscle tone, associated with narcolepsy; Orphan Medical; Approved July 2002
Drugs Approved in 2001
Axert (almotriptan malate) tablets; For the treatment of migraine attacks; Pharmacia; Approved May 2001
Bayer Extra Strength Asprin; Oral treatment for mild to moderate migraine pain; Bayer; Approved October 2001
Focalin (dexmethylphenidate HCl); For the treatment of attention deficit hyperactivity disorder (ADHD); Celgene; Approved November 2001
Frova (frovatriptan succinate); Tablets for the acute treatment of migraine attacks; Elan; Approved November 2001
Metadate CD; Oral capsules for the treatment of attention deficit hyperactivity disorder; Celltech Pharmaceuticals; Approved April 2001
Reminyl (galantamine hydrobromide); For the treatment of mild to moderate dementia of the Alzheimer's type; Janssen Pharmaceutica; Approved February 2001
Ultracet (acetaminophen and tramadol HCl); For the short-term management of acute pain; Ortho-McNeil Pharmaceutical; Approved August 2001
Zomig-ZMT (zolmitriptan); Orally disintegrating tablet for the treatment of acute migraine in adults; AstraZeneca; Approved February 2001
Drugs Approved in 2000
Depakote ER (divalproex sodium); For the prophylaxis (prevention) of migraine headaches in adults; Abbott Laboratories; Approved August 2000
Exelon (rivastigmine tartrate); Indicated for the treatment of mild to moderate dementia of the Alzheimer's type; Novartis; Approved April 2000
Myobloc; Injectable solution for the treatment of abnormal head position and neck pain associated with cervical dystonia; Elan; Approved December 2000
Neurontin (gabapentin) Oral Solution; For the treatment of partial seizures in pediatric patients three years of age and older; Parke-Davis; Approved October 2000
Neurontin (gabapentin) oral solution; Treatment of partial seizures in adults with epilepsy; Parke-Davis; Approved March 2000
Novantrone (mitoxantrone hydrochloride); For reducing neurologic disability and/or the frequency of clinical relapses in patients with multiple sclerosis; Immunex; Approved October 2000
Trileptal (oxcarbazepine) Tablets; Approved for use as adjunctive therapy in the treatment of partial seizures in children (monotherapy for adults); Novartis; Approved January 2000
Zonegran (zonisamide) Capsules; Adjunctive therapy for treatment of partial seizures in adults with epilepsy; Dainippon Pharmaceutical; Approved March 2000
Drugs Approved in 1999
Aggrenox; Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke; Boehringer Ingelheim; Approved November 1999
Cenestin; Treatment for symptoms associated with menopause; Duramed Pharmaceuticals; Approved July 1999
Comtan; 200mg entacapone tablets; Novartis; October 19, 1999
Keppra; Levetiracetam tablets for adjunctive treatment of partial onset seizures in adults with epilepsy; UCB Pharma; Approved November 1999
Lamictal (lamotrigine) Chewable Dispersible Tablet; Treatment for epileptic seizures; GlaxoWellcome; Approved June 1999
Lidoderm Patch (lidocaine patch 5% ); Treatment of pain in post-herpetic neuralgia; Hind Health Care; Approved June 1999
Sonata; Treatment fo insomnia; American Home Products; Approved August 1999
Topamax; Treatment for epilepsy in pediatric patients; Ortho-McNeil Pharmaceutical; Approved July 1999
Drugs Approved in 1998
Amerge; Treatment for acute migraine; GlaxoWellcome; Approved February 1998
Clonazepam; Generic equivalent of Klonopin; Watson Pharmaceuticals; Approved January 1998
Cylert; Treatment for Attention Deficit Disorder; Abbott Laboratories; Approved October 1998
Excedrin Migraine; Treatment for mild to moderate migraine pain; Bristol-Myers Squibb; Approved January 1998
Lamictal Chewable Dispersible Tablets; Treatment for Epilepsy; GlaxoWellcome; Approved August 1998
Maxalt; Acute treatment of migraine headache; Merck; Approved June 1998
Naltrexone Hydrochloride Tablets; Generic equivalent of Revia; Barr Laboratories; Approved May 1998
Oxycodone and Aspirin; Generic equivalent of Percodan; Watson Pharmaceuticals; Approved March 1998
Tasmar; Treatment for Parkinson's Disease; Roche; Approved January 1998
Drugs Approved in 1997
Bromfenac; Management of acute pain; Duract, Wyeth-Ayerst Laboratories; Approved July 1997
Carbatrol; Treatment for epileptic seizures and trigeminal neuralgia; Elan; Approved September 1997
Copaxone; Treatment for relapsing-remitting multiple sclerosis; Teva Pharmaceutical; Approved January 1997
Galzin (zinc acetate); Treatment for Wilson’s disease; Teva Pharmaceutical; Approved January 1997
Imitrex (sumatriptan); Treatment for migraine headaches; GlaxoWellcome; Approved August 1997
Imitrex Nasal Spray; Treatment for migraine; GlaxoWellcome; Approved November 1997
Migranal; Treatment for migraine headaches; Novartis; Approved December 1997
Mirapex; Treatment for Parkinson’s Disease; Pharmacia & Upjohn, Boehringer Ingelheim; Approved June 1997
|
|
Back to Centerwatch Drug Approvals
|
